Jetema
Jetema is a Korean bio-aesthetic pharmaceutical company that develops, manufactures, and globally commercializes botulinum toxin, hyaluronic acid fillers, PDO lifting threads, and skin boosters for medical aesthetic clinics, primarily through exclusive international distribution contracts and direct Korean sales.
- Company typePublic
- Founded2009
- HeadquartersWonju, South Korea
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
What Jetema does
JETEMA, Co., Ltd. is a Korean research-oriented bio-aesthetic pharmaceutical company founded in 2009 and headquartered in Wonju, South Korea. The company develops, manufactures, and commercializes a comprehensive portfolio of aesthetic medicine products spanning four categories: pharmaceutical products (JETEMA THE TOXIN, a botulinum toxin type A), medical devices (e.p.t.q. hyaluronic acid dermal fillers, epiticon PDO lifting threads, Ecolla PLLA skin booster), mesotherapy solutions (vitten), and cosmetics (Vitten, EXO'LUTION, e.p.t.q. Skin Care, e.p.t.q. By.derm). Its core technology rests on proprietary low-modification-degree HA filler manufacturing (achieving 1.89% MoD versus competitor benchmarks of 6-8%) and legitimate commercialization rights to the ATCC3502 botulinum toxin strain acquired in 2016, produced at Korea's largest cGMP-compliant botulinum toxin manufacturing facility.
JETEMA generates revenue through a hybrid B2B model: direct sales to aesthetic and plastic surgery clinics in its domestic Korean market, combined with exclusive supply and out-licensing contracts with regional pharmaceutical distributors across China, Brazil, the UK, Russia, the Middle East, Vietnam, Thailand, and other markets. The company has signed mega-distribution deals including a $459 million supply contract with Huadong Ningbo Medicine for China and a $120 million contract with Funshine for Brazil. JETEMA listed on KOSDAQ (ticker: 332570) in November 2019, reported 40% average annual sales growth over the four years through 2023, and has established wholly-owned subsidiaries in the United States (Irvine, CA, 2022) and China (Shanghai, 2021) to support FDA clinical trials and direct market entry. Recent regulatory milestones include Korean KFDA marketing authorization for THE TOXIN (December 2024), domestic Korean launch (March 2025), and NMPA approval for e.p.t.q. S500 in China (April 2025). The company is co-led by CEOs Kim Jaeyoung and Nam Jeongsun and operates manufacturing facilities in Wonju and Yongin alongside a global R&D center in Pangyo.
Jetema firmographics
Firmographics- Name
- Jetema
- Legal name
- JETEMA, Co., Ltd.
- Website
- https://jetema.com
- Company type
- Public
- Founded year
- 2009
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- Jetema is a Korean bio-aesthetic pharmaceutical company that develops, manufactures, and globally commercializes botulinum toxin, hyaluronic acid fillers, PDO lifting threads, and skin boosters for medical aesthetic clinics, primarily through exclusive international distribution contracts and direct Korean sales.
- Ownership category
- akta.pro rank
Jetema industry classification
Industry- Product category
- Aesthetic Medicine Pharmaceuticals and Medical Devices
- NAICS
- Medicinal and Botanical Manufacturing (325411), Soap and Cleaning Compound Manufacturing (32561)
- SIC
- Pharmaceutical Preparations (2834), Perfumes, Cosmetics & Other Toilet Preparations (2844)
- akta.pro primary industry
- Dermatology & Aesthetics Pharmaceuticals (HLAIAAAK)
- akta.pro secondary industries
- Hand & Body Care (Lotions, Creams, Body Oils) (CRADANAC), Dermatology OTC & Skin Health (Acne Treatments, Eczema/Psoriasis OTC, Antifungals, Wart Removal) (CRADAMAF)
Keywords
Where Jetema is headquartered
LocationHeadquarters
- HQ city
- Wonju
- HQ country
- South Korea
- HQ region
- Asia
Offices6 records
Markets served
Jetema business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Operations, Technology or R&D, Personnel, Marketing or Sales, Infrastructure
Revenue model
- Pharmaceutical Products: Revenue from botulinum toxin products (JETEMA THE TOXIN) sold for both domestic Korean market and export. The company has obtained domestic marketing authorization for THE TOXIN 100U and is expanding clinical trials globally.
- Medical Devices: Revenue from HA fillers (e.p.t.q.), PDO threads (Epiticon), and medical device moisturizers (By.derm). Products sold through distributors globally.
- Cosmetics: Revenue from cosmetics products including Vitten, EXO'LUTION, e.p.t.q. Skin Care, and By.derm products sold through various channels.
- Meso Solutions: Revenue from meso solution products like Vitten for aesthetic medicine applications.
- Licensing and Supply Contracts: Revenue from out-licensing agreements and exclusive supply contracts with international partners including $459M contract with Huadong Ningbo Medicine for China market.
Go-to-market motion2 records
Distribution channels6 records
Marketing channels7 records
Jetema product offering
Product offeringCore offering
Jetema develops, manufactures, and sells pharmaceutical products (botulinum toxin JETEMA THE TOXIN), medical devices (e.p.t.q. HA dermal fillers, epiticon PDO lifting threads, Ecolla PLLA skin booster, prajué PN skin booster), meso solutions (vitten), and cosmetics (Vitten, EXO'LUTION, e.p.t.q. Skin Care, e.p.t.q. By.derm) for the global aesthetic medicine market, sold through exclusive regional distributors and wholly-owned subsidiaries.
Product overview
JETEMA is a bio venture company that develops and manufactures pharmaceutical products, medical devices, and cosmetics for the aesthetic medicine market. The product portfolio is organized into four main categories: (1) Pharmaceutical Products — JETEMA THE TOXIN® (botulinum toxin type A for export); (2) Medical Devices — including the e.p.t.q.® HA dermal filler line (with lidocaine variants S100/S300/S500), epiticon® PDO lifting threads (Original and Thin), and Ecolla™ PLLA skin booster; (3) Meso Solutions — vitten® mesotherapy products including an injector device; (4) Cosmetics — including Vitten®, EXO'LUTION® skinbooster, e.p.t.q.® Skin Care, and e.p.t.q. By.derm® medical device moisturizers. Recent launches include prajué (PN skin booster, July 2024), Ecolla S (PLLA skin booster, August 2024), 순수필 HA filler (April 2024), and Lénafill HA filler (March 2023). The company operates cGMP-compliant manufacturing facilities in Wonju and Yongin, Korea.
Differentiator
Problem solved
Functional benefit
Brands
- JETEMA THE TOXIN: Botulinum toxin pharmaceutical product (For export)
- e.p.t.q.
- epiticon
- Vitten
- EXO'LUTION
- e.p.t.q. By.derm
- e.p.t.q. Skin Care
- Ecolla
- Lenafill
- prajué
Products and services
- JETEMA THE TOXIN Botulinum toxin type A pharmaceutical product approved for improving glabellar lines, with Phase 2 clinical trials approved by U.S. FDA and ongoing Phase 3 trials in China and Korea for additional indications including upper limb muscle spasticity. Sold for both domestic Korean market and international export.
- e.p.t.q. Hyaluronic acid dermal filler product line with proprietary low-MoD (1.89%) technology, available in lidocaine variants S100, S300, and S500 in 0.5ml, 1.0ml, and 2.0ml volumes for facial dermal filling procedures. CE marked, ANVISA approved, and NMPA (China) approved.
- epiticon Polydioxanone (PDO) lifting thread product line (Original and Thin variants) for facial and body lifting procedures, backed by patents in Thailand and Russia. Manufactured at Jetema's PDO suture factory established in April 2023.
- Ecolla PLLA (poly-L-lactic acid) skin booster product line for skin rejuvenation applications, launched in August 2024.
- vitten Meso solution product line for mesotherapy treatments, including an injector device, used by aesthetic medicine practitioners for skin rejuvenation procedures.
- EXO'LUTION Skinbooster product for skin hydration and rejuvenation, launched in Korea in January 2023.
- Lenafill Hyaluronic acid filler launched in Korea in March 2023 as a new HA filler offering in Jetema's filler portfolio.
- prajué PN (polynucleotide) skin booster launched in Korea in July 2024 for skin rejuvenation applications.
- e.p.t.q. By.derm MD Medical device moisturizer cream for protecting skin with damaged barriers, part of the e.p.t.q. By.derm medical device moisturizer line.
Quantifiable outcome
- 40% average annual sales growth rate over four years
- +1 more outcomes
Companies that use Jetema
Customer profileNamed customers7 records
Segments3 records
Ideal customer profiles3 records
Jetema technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Jetema partnerships and signals
Strategic signalPartnerships
Nine partnerships are on record, tiered core, major and minor.
- Huadong Ningbo Medicinecore$459 million supply contract with $12.5 million advance license fee for entering Chinese toxin market. Huadong Ningbo will initiate local clinical trial for marketing license in China and achieve local approval.
- epique UK Ltdmajor$12 million supply contract for e.p.t.q. filler covering UK and Ireland markets.
- Dong Wha PharmcoreJoint development MOU for botulinum toxin product. Agreement aims for new indication development and approval through mutual cooperation and joint study.
- Russian Companymajor$6.6 million exclusive supply contract for hyaluronic acid filler, recognizing excellent safety and efficacy of Jetema's filler e.p.t.q.
- NEDALmajor5-year partnership with Jordan company for exclusive supply of e.p.t.q. filler worth $2.5 million. License acquisition within 6 months required.
- Funshinecore$120 million supply contract and local clinical trial for THE TOXIN with Brazilian local company Funshine. Local marketing approval and launching planned by 2023.
- Vietnamese ClinicsmajorStrategic partnership with famous aesthetic clinics in Vietnam following formal import and distribution license approval in April 2018. VIP launching ceremony held with ambassador Kwon Sang-woo.
- Kyung Hee University, College of PharmacyminorMOU for cooperative research and academic excellence program to build organic cooperation research system, conduct collaborative research through mutual exchange and cooperation, and train talented individuals.
- Hanmi PharmaceuticalcoreJetema partnered with Hanmi Pharmaceutical to repurpose a joint treatment product for cosmetic use, expanding beyond single-product revenue structures.
Scale indicators11 records
Recent moves13 records
Expansion highlights6 records
Jetema competitors and assessment
Company assessmentEmerging players
- Evolus: US-focused aesthetic company marketing Jeuveau (prabotulinumtoxinA), a botulinum toxin positioned as a value alternative to Botox. Evolus represents the type of focused toxin challenger Jetema would face upon potential US entry.
- Revance Therapeutics: Aesthetic and therapeutic company developing DaxibotulinumtoxinA (Daxxify), a long-duration botulinum toxin, plus the RHA Collection of fillers. Revance is a US-based emerging aesthetic competitor overlapping with Jetema's toxin and filler ambitions.
- Croma-Pharma: Austria-headquartered company specializing in HA fillers (Princess series), PDO threads, and aesthetic medicine products sold primarily in Europe and emerging markets. Croma is comparable to Jetema as a non-incumbent aesthetic specialist with parallel product categories including threads.
Broad incumbents
- AbbVie (Allergan Aesthetics): Owner of Botox (botulinum toxin) and the broader aesthetic medicine franchise including CoolSculpting. AbbVie/Allergan is the global market leader in aesthetic toxins and the primary competitive incumbent Jetema's THE TOXIN would need to displace in the US and Europe.
- Merz Aesthetics: Aesthetic division of Merz Group offering Xeomin (botulinum toxin), Belotero (HA filler), Radiesse (CaHA), and Ultherapy. Merz competes with Jetema across both the toxin and filler categories globally.
- Galderma: Global dermatology-focused company producing the Juvederm and Restylane HA filler families, Sculptra (PLLA), and other aesthetic products. Galderma is the leading HA filler incumbent whose MoD and crosslinking technology Jetema explicitly benchmarks its e.p.t.q. fillers against.
- Ipsen: Global pharmaceutical company that markets Dysport/Azzalure botulinum toxin and other aesthetic products. Ipsen is one of the major global aesthetic toxin competitors alongside Botox and Xeomin.
Direct peers
- Daewoong Pharmaceutical: Korean pharma company that developed Nabota, a botulinum toxin that received FDA approval. Daewoong competes with Jetema in both domestic Korean toxin markets and in the global export channels where Korean aesthetic products are positioned.
- Hugel: Korean manufacturer of Botulax (botulinum toxin type A) and dermal fillers, with both domestic Korean market presence and expanding global distribution. Hugel is the most direct comparable to Jetema's THE TOXIN and e.p.t.q. filler portfolio and competes head-to-head in Korea and emerging markets.
- Medytox: Korean biopharmaceutical company developing Neuronox (botulinum toxin) and aesthetic products including fillers. Medytox overlaps directly with Jetema's core toxin and filler portfolio and shares the Korean-origin export narrative into US and emerging markets.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
Jetema social profiles
Digital presenceJetema compliance and trust
Trust signalCompliance10 records
Jetema financial estimates
Financial estimateRevenue estimate
Valuation estimate
Jetema leadership team
Management profileNumber of profiles
Profiles3 records
Jetema subsidiaries and ownership
Company hierarchySubsidiaries3 records
Jetema funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Jetema M&A and investment
M&A and investmentM&A
Investments2 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Jetema
What does Jetema do?
Jetema develops, manufactures, and sells pharmaceutical products (botulinum toxin JETEMA THE TOXIN), medical devices (e.p.t.q. HA dermal fillers, epiticon PDO lifting threads, Ecolla PLLA skin booster, prajué PN skin booster), meso solutions (vitten), and cosmetics (Vitten, EXO'LUTION, e.p.t.q. Skin Care, e.p.t.q. By.derm) for the global aesthetic medicine market, sold through exclusive regional distributors and wholly-owned subsidiaries.
Is Jetema a public or private company?
Jetema is a public company. It is classified as public and is currently operating.
When was Jetema founded?
Jetema was founded in 2009. It employs 101 to 250 people.
Where is Jetema based?
Jetema is headquartered in Wonju, South Korea, in the Asia region.
How does Jetema make money?
Five revenue lines are on record. Pharmaceutical Products are the primary driver. The others are medical Devices, cosmetics, meso Solutions and licensing and Supply Contracts.
Who are Jetema's main competitors?
Emerging players on record are Evolus, Revance Therapeutics and Croma-Pharma. Broad incumbents are AbbVie (Allergan Aesthetics), Merz Aesthetics, Galderma and Ipsen. Direct peers are Daewoong Pharmaceutical, Hugel and Medytox.
Does Jetema have an API?
No public API is recorded for Jetema.
What industry is Jetema in?
Jetema's product category is Aesthetic Medicine Pharmaceuticals and Medical Devices. Its primary akta.pro industry code is HLAIAAAK, Dermatology & Aesthetics Pharmaceuticals, with a secondary code of CRADANAC, Hand & Body Care (Lotions, Creams, Body Oils). Its NAICS code is 325411 and its SIC code is 2834.